173 related articles for article (PubMed ID: 36671443)
1. Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma.
Chen S; Zhang L; Lin H; Liang Y; Wang Y
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671443
[TBL] [Abstract][Full Text] [Related]
2. Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma.
Du K; Wei S; Wei Z; Frederick DT; Miao B; Moll T; Tian T; Sugarman E; Gabrilovich DI; Sullivan RJ; Liu L; Flaherty KT; Boland GM; Herlyn M; Zhang G
Nat Commun; 2021 Oct; 12(1):6023. PubMed ID: 34654806
[TBL] [Abstract][Full Text] [Related]
3. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
Liu D; Schilling B; Liu D; Sucker A; Livingstone E; Jerby-Arnon L; Zimmer L; Gutzmer R; Satzger I; Loquai C; Grabbe S; Vokes N; Margolis CA; Conway J; He MX; Elmarakeby H; Dietlein F; Miao D; Tracy A; Gogas H; Goldinger SM; Utikal J; Blank CU; Rauschenberg R; von Bubnoff D; Krackhardt A; Weide B; Haferkamp S; Kiecker F; Izar B; Garraway L; Regev A; Flaherty K; Paschen A; Van Allen EM; Schadendorf D
Nat Med; 2019 Dec; 25(12):1916-1927. PubMed ID: 31792460
[TBL] [Abstract][Full Text] [Related]
4. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
Auslander N; Zhang G; Lee JS; Frederick DT; Miao B; Moll T; Tian T; Wei Z; Madan S; Sullivan RJ; Boland G; Flaherty K; Herlyn M; Ruppin E
Nat Med; 2018 Oct; 24(10):1545-1549. PubMed ID: 30127394
[TBL] [Abstract][Full Text] [Related]
5. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma.
Coleman S; Xie M; Tarhini AA; Tan AC
Mol Carcinog; 2023 Jan; 62(1):77-89. PubMed ID: 35781709
[TBL] [Abstract][Full Text] [Related]
6. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
7. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
8. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
9.
Parakh S; Musafer A; Paessler S; Witkowski T; Suen CSNLW; Tutuka CSA; Carlino MS; Menzies AM; Scolyer RA; Cebon J; Dobrovic A; Long GV; Klein O; Behren A
Front Immunol; 2021; 12():672521. PubMed ID: 34177913
[TBL] [Abstract][Full Text] [Related]
10. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
[TBL] [Abstract][Full Text] [Related]
11. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
[TBL] [Abstract][Full Text] [Related]
12. A multi-omic single cell sequencing approach to develop a CD8 T cell specific gene signature for anti-PD1 response in solid tumors.
Kumar N; Papillon-Cavanagh S; Tang H; Wang S; Stromko C; Ho CP; Soni-Sheth S; Vasquez-Grinnell S; Broz ML; Tenney DJ; Wichroski MJ; Walsh AM; Hu Y; Benci JL
Int J Cancer; 2022 Dec; 151(11):2043-2054. PubMed ID: 35932450
[TBL] [Abstract][Full Text] [Related]
13. High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.
Onieva JL; Xiao Q; Berciano-Guerrero MÁ; Laborda-Illanes A; de Andrea C; Chaves P; Piñeiro P; Garrido-Aranda A; Gallego E; Sojo B; Gálvez L; Chica-Parrado R; Prieto D; Pérez-Ruiz E; Farngren A; Lozano MJ; Álvarez M; Jiménez P; Sánchez-Muñoz A; Oliver J; Cobo M; Alba E; Barragán I
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012390
[TBL] [Abstract][Full Text] [Related]
14. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
15. Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy.
Vanmeerbeek I; Borras DM; Sprooten J; Bechter O; Tejpar S; Garg AD
Genes Immun; 2021 Jun; 22(2):108-119. PubMed ID: 34079092
[TBL] [Abstract][Full Text] [Related]
16. A Comprehensive Prognostic and Immunological Analysis of a Six-Gene Signature Associated With Glycolysis and Immune Response in Uveal Melanoma.
Liu J; Lu J; Li W
Front Immunol; 2021; 12():738068. PubMed ID: 34630418
[TBL] [Abstract][Full Text] [Related]
17. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
18. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract][Full Text] [Related]
19. Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab.
Friedlander P; Wassmann K; Christenfeld AM; Fisher D; Kyi C; Kirkwood JM; Bhardwaj N; Oh WK
J Immunother Cancer; 2017 Aug; 5(1):67. PubMed ID: 28807052
[TBL] [Abstract][Full Text] [Related]
20. A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma.
Girault I; Adam J; Shen S; Roy S; Brard C; Faouzi S; Routier E; Lupu J; Warren S; Sorg K; Ong S; Morel P; Scoazec JY; Vagner S; Robert C
Clin Cancer Res; 2022 Feb; 28(3):518-525. PubMed ID: 34785583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]